Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
复制标题
DOI：
10.1016/j.cell.2021.02.035
复制
发表时间：
2021-04-01
期刊：
影响因子：
64.5
通讯作者：
Rappuoli R
中科院分区：
文献类型：
--
作者：
Andreano E;Nicastri E;Paciello I;Pileri P;Manganaro N;Piccini G;Manenti A;Pantano E;Kabanova A;Troisi M;Vacca F;Cardamone D;De Santi C;Torres JL;Ozorowski G;Benincasa L;Jang H;Di Genova C;Depau L;Brunetti J;Agrati C;Capobianchi MR;Castilletti C;Emiliozzi A;Fabbiani M;Montagnani F;Bracci L;Sautto G;Ross TM;Montomoli E;Temperton N;Ward AB;Sala C;Ippolito G;Rappuoli R
人类单克隆抗体是安全、预防和治疗的工具，可以快速开发，以帮助恢复2019年冠状病毒病（COVID-19）大流行造成的大规模健康和经济破坏。通过对14名COVID-19幸存者的4,277个SARS-CoV-2刺突蛋白特异性记忆B细胞进行单细胞分选，鉴定出453种中和抗体。最有效的中和抗体识别刺突蛋白受体结合结构域，其次是识别S1结构域、刺突蛋白三聚体和S2亚基的抗体。只有1.4%的菌株能中和真实病毒，效价为1-10 ng/mL。最有效的单克隆抗体，经工程改造，以降低抗体依赖性增强的风险和延长半衰期，中和了真正的野生型病毒和含有D 614 G，E484 K和N501 Y取代的新变体。在不存在Fc功能的情况下，分别在0.25和4 mg/kg剂量下观察到仓鼠模型的预防和治疗疗效。极有效的中和人单克隆抗体虽然罕见，但从COVID-19康复期患者中分离出来，适用于野生型SARS-CoV-2以及新出现的变体的预防和治疗干预。
Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. By single-cell sorting 4,277 SARS-CoV-2 spike protein-specific memory B cells from 14 COVID-19 survivors, 453 neutralizing antibodies were identified. The most potent neutralizing antibodies recognized the spike protein receptor-binding domain, followed in potency by antibodies that recognize the S1 domain, the spike protein trimer, and the S2 subunit. Only 1.4% of them neutralized the authentic virus with a potency of 1–10 ng/mL. The most potent monoclonal antibody, engineered to reduce the risk of antibody-dependent enhancement and prolong half-life, neutralized the authentic wild-type virus and emerging variants containing D614G, E484K, and N501Y substitutions. Prophylactic and therapeutic efficacy in the hamster model was observed at 0.25 and 4 mg/kg respectively in absence of Fc functions. Extremely potent neutralizing human monoclonal antibodies, though rare, are isolated from COVID-19 convalescent patients and suitable for prophylactic and therapeutic interventions of wild-type SARS-CoV-2 as well as emerging variants.
登录
查看更多内容
影响因子：
5.4
作者：
Ackerman, Margaret E.;Dugast, Anne-Sophie;Alter, Galit
通讯作者：
Alter, Galit
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
DOI：
10.4049/jimmunol.2000583
发表时间：
2020-08-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Alsoussi WB;Turner JS;Case JB;Zhao H;Schmitz AJ;Zhou JQ;Chen RE;Lei T;Rizk AA;McIntire KM;Winkler ES;Fox JM;Kafai NM;Thackray LB;Hassan AO;Amanat F;Krammer F;Watson CT;Kleinstein SH;Fremont DH;Diamond MS;Ellebedy AH
通讯作者：
Ellebedy AH
影响因子：
2.2
作者：
Karsten, Christina B.;Mehta, Nickita;Alter, Galit
通讯作者：
Alter, Galit
影响因子：
56.9
作者：
Hsieh, Ching-Lin;Goldsmith, Jory A.;McLellan, Jason S.
通讯作者：
McLellan, Jason S.